{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:13:46Z","timestamp":1788387226468,"version":"build-2803163510"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"DOI":"10.1038\/boneres.2014.44","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T12:17:56Z","timestamp":1419337076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Chronic kidney disease and the skeleton"],"prefix":"10.1038","volume":"2","author":[{"given":"Paul D","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"BFboneres201444_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","volume":"64","author":"PD Miller","year":"2014","unstructured":"Miller PD . Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 2014; 64: 290\u2013304.","journal-title":"Am J Kidney Dis"},{"key":"BFboneres201444_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/bonekey.2014.37","volume":"3","author":"PD Miller","year":"2014","unstructured":"Miller PD . Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep 2014; 3: 542.","journal-title":"Bonekey Rep"},{"key":"BFboneres201444_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","volume":"41","author":"J Coresh","year":"2013","unstructured":"Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS . Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2013; 41: 1\u201312.","journal-title":"Am J Kidney Dis"},{"key":"BFboneres201444_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137\u2013147.","journal-title":"Ann Intern Med"},{"key":"BFboneres201444_CR5","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089\u20132100.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMe058035","volume":"352","author":"LA Stevens","year":"2005","unstructured":"Stevens LA, Levey AS . Chronic kidney disease in the elderly\u2014how to assess risk. N Engl J Med 2005; 352: 2122\u20132124.","journal-title":"N Engl J Med"},{"key":"BFboneres201444_CR7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Coresh J, Greene T, Levey AS . Assessing kidney function\u2014measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473\u20132483.","journal-title":"N Engl J Med"},{"key":"BFboneres201444_CR8","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis 2002; 39: S1\u2013S266.","journal-title":"Am J Kidney Dis"},{"key":"BFboneres201444_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/ki.2009.178","volume":"76","author":"GM Kirsztajn","year":"2009","unstructured":"Kirsztajn GM, Suassuna JH, Bastos MG . Dividing stage 3 of chronic kidney disease (CKD): 3A and 3B. Kidney Int 2009; 76: 462\u2013463; author reply 463\u2013464.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/jbmr.170","volume":"25","author":"H J\u00fcppner","year":"2010","unstructured":"J\u00fcppner H, Wolf M, Salusky IB . FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25: 2091\u20132097.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrneph.2013.147","volume":"9","author":"J Silver","year":"2013","unstructured":"Silver J, Naveh-Many T . FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; 9: 641\u2013649.","journal-title":"Nat Rev Nephrol"},{"key":"BFboneres201444_CR12","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD). Kidney Int Suppl 2009; (113): S1\u2013S130."},{"key":"BFboneres201444_CR13","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/ndt\/13.9.2294","volume":"13","author":"G Coen","year":"1998","unstructured":"Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294\u20132302.","journal-title":"Nephrol Dial Transplant"},{"key":"BFboneres201444_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/oxfordjournals.ndt.a027457","volume":"11","author":"MM Couttenye","year":"1996","unstructured":"Couttenye MM, D\u2019Haese PC, van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065\u20131072.","journal-title":"Nephrol Dial Transplant"},{"key":"BFboneres201444_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.09580911","volume":"8","author":"G Garrett","year":"2013","unstructured":"Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ . PTH\u2014a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol 2013; 8: 299\u2013312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFboneres201444_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785\u2013795.","journal-title":"JAMA"},{"key":"BFboneres201444_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11154-006-9006-0","volume":"7","author":"PD Miller","year":"2006","unstructured":"Miller PD . Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 2006; 7: 75\u201389.","journal-title":"Rev Endocr Metab Disord"},{"key":"BFboneres201444_CR18","first-page":"1","volume":"843","author":"Assessment of fracture risk and its","year":"1994","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis . Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1\u2013129.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"BFboneres201444_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jbmr.5650100202","volume":"10","author":"Melton LJ 3rd","year":"1995","unstructured":"Melton LJ 3rd. How many women have osteoporosis now? J Bone Miner Res 1995; 10: 175\u2013177.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","volume":"11","author":"S Baim","year":"2008","unstructured":"Baim S, Binkley N, Bilezikian JP et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11: 75\u201391.","journal-title":"J Clin Densitom"},{"key":"BFboneres201444_CR21","first-page":"404","volume":"4","author":"ML Bouxsein","year":"2004","unstructured":"Bouxsein ML . Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact 2004; 4: 404\u2013405.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"BFboneres201444_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-007-0793-5","volume":"26","author":"E Seeman","year":"2008","unstructured":"Seeman E . Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 2008; 26: 1\u20138.","journal-title":"J Bone Miner Metab"},{"key":"BFboneres201444_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385\u2013397.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR24","first-page":"226","volume":"14","author":"K Engelke","year":"2013","unstructured":"Engelke K, Adams JE, Armbrecht G et al. Implementation and use of FRAX in clinical practice. J Clin Densitom 2013; 14: 226\u2013236.","journal-title":"J Clin Densitom"},{"key":"BFboneres201444_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-013-2409-3","volume":"25","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Lix LM . Comparison between various fracture risk assessment tools. Osteoporos Int 2014; 25: 1\u201321.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR26","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jbmr.499","volume":"26","author":"D Hans","year":"2011","unstructured":"Hans D, Goertzen AL, Krieg MA, Leslie WD . Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 2011; 26: 2762\u20132769.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1749-6632.2009.05348.x","volume":"1192","author":"TM Keaveny","year":"2010","unstructured":"Keaveny TM . Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans. Ann NY Acad Sci 2010; 1192: 57\u201365.","journal-title":"Ann NY Acad Sci"},{"key":"BFboneres201444_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jocd.2013.05.001","volume":"17","author":"D Krueger","year":"2014","unstructured":"Krueger D, Fidler E, Libber J, Aubier-Rozier B, Hans D, Binkley N . Spine trabecular bone score subsequent to bone mineral density improves fracture discrimination in women. J Clin Densitom 2014; 17: 60\u201365.","journal-title":"J Clin Densitom"},{"key":"BFboneres201444_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H et al. Trabecular Bone Score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 2014; 29: 518\u2013530.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archinte.167.2.133","volume":"167","author":"KE Ensrud","year":"2007","unstructured":"Ensrud KE, Lui LY, Taylor BC et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167: 133\u2013139.","journal-title":"Arch Intern Med"},{"key":"BFboneres201444_CR31","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-005-1903-7","volume":"16","author":"L Dukas","year":"2005","unstructured":"Dukas L, Schacht E, St\u00e4helin HB . In elderly men and women treated for osteoporosis a low creatinine clearance of < 65 ml\/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16: 1683\u20131690.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1681\/ASN.2006050546","volume":"18","author":"LF Fried","year":"2007","unstructured":"Fried LF, Biggs ML, Shlipak MG et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 2007; 18: 282\u2013286.","journal-title":"J Am Soc Nephrol"},{"key":"BFboneres201444_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1681\/ASN.2010121275","volume":"22","author":"TL Nickolas","year":"2011","unstructured":"Nickolas TL, Cremers S, Zhang A et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1560\u20131572.","journal-title":"J Am Soc Nephrol"},{"key":"BFboneres201444_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ki.2008.264","volume":"74","author":"TL Nickolas","year":"2008","unstructured":"Nickolas TL, Leonard MB, Shane E . Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008; 74: 721\u2013731.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396\u2013399.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR36","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","volume":"288","author":"AM Ball","year":"2002","unstructured":"Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014\u20133018.","journal-title":"JAMA"},{"key":"BFboneres201444_CR37","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358\u20131366.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR38","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/j.1523-1755.2000.00394.x","volume":"58","author":"CO Stehman-Breen","year":"2000","unstructured":"Stehman-Breen CO, Sherrard DJ, Alem AM et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 2200\u20132205.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR39","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2215\/CJN.06300613","volume":"8","author":"KE Ensrud","year":"2013","unstructured":"Ensrud KE . Fracture risk in CKD. Clin J Am Soc Nephrol 2013; 8: 1282\u20131283.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFboneres201444_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11926-012-0243-9","volume":"14","author":"SA Jamal","year":"2012","unstructured":"Jamal SA, West SL, Miller PD . Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep 2012; 14: 217\u2013223.","journal-title":"Curr Rheumatol Rep"},{"key":"BFboneres201444_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ecl.2012.05.005","volume":"41","author":"PD Miller","year":"2012","unstructured":"Miller PD . Unrecognized and underappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012; 41: 613\u2013628.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"BFboneres201444_CR42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/jbmr.170","volume":"25","author":"H J\u00fcppner","year":"2010","unstructured":"J\u00fcppner H, Wolf M, Salusky IB . FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25: 2091\u20132097.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR43","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dikkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877\u2013882.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFboneres201444_CR44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jbmr.5650020617","volume":"2","author":"AM Parfitt","year":"1987","unstructured":"Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595\u2013610.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Dreznar MK et al. Standarized nomenclature, symbols, and units for bone histomorphonetry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28: 2\u201317.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR46","first-page":"2735","volume-title":"Diseases of the kidney and urinary tract","author":"DL Andress","year":"2003","unstructured":"Andress DL, Sherrard DJ . The osteodystrophy of chronic renal failure. In: Schrier RW, editor. Diseases of the kidney and urinary tract. Philadelphia, PA: Lippincott Williams and Wilkins, 2003: 2735\u20132768."},{"key":"BFboneres201444_CR47","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2215\/CJN.02430508","volume":"3","author":"PD Miller","year":"2008","unstructured":"Miller PD . The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008; 3(Suppl 3): S140\u2013S150.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFboneres201444_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF02058664","volume":"3","author":"HM Frost","year":"1969","unstructured":"Frost HM . Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969; 3: 211\u2013237.","journal-title":"Calcif Tissue Res"},{"key":"BFboneres201444_CR49","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1139\/y70-118","volume":"48","author":"O Hitt","year":"1970","unstructured":"Hitt O, Jaworski ZF, Shimizu AG, Frost HM . Tissue-level bone formation rates in chronic renal failure, measured by means of tetracycline bone labeling. Can J Physiol Pharmacol 1970; 48: 824\u2013828.","journal-title":"Can J Physiol Pharmacol"},{"key":"BFboneres201444_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00041552-200307000-00007","volume":"12","author":"AM Parfitt","year":"2003","unstructured":"Parfitt AM . Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387\u2013403.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFboneres201444_CR51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1046\/j.1525-139X.2003.160631.x","volume":"16","author":"D Trueba","year":"2003","unstructured":"Trueba D, Sawaya BP, Mawad H, Malluche HH . Bone biopsy: indications, techniques, and complications. Semin Dial 2003; 16: 341\u2013345.","journal-title":"Semin Dial"},{"key":"BFboneres201444_CR52","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"PD Miller","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S . Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 2013; 28: 2049\u20132059.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1525-139X.2007.00319.x","volume":"20","author":"A Gal-Moscovici","year":"2007","unstructured":"Gal-Moscovici A, Sprague SM . Osteoporosis and chronic kidney disease. Semin Dial 2007; 20: 423\u2013430.","journal-title":"Semin Dial"},{"key":"BFboneres201444_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/000456307779596039","volume":"44","author":"EJ Lamb","year":"2007","unstructured":"Lamb EJ, Vickery S, Ellis AR . Parathyroid hormone, kidney disease, evidence and guidelines. Ann Clin Biochem 2007; 44(Pt 1): 1\u20134.","journal-title":"Ann Clin Biochem"},{"key":"BFboneres201444_CR55","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00198-011-1781-0","volume":"23","author":"SA Jamal","year":"2012","unstructured":"Jamal SA, West SL, Miller PD . Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2012; 23: 1191\u20131198.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR56","doi-asserted-by":"publisher","first-page":"500","DOI":"10.4158\/EP12291.RA","volume":"20","author":"F Zangeneh","year":"2014","unstructured":"Zangeneh F, Clarke BL, Hurley DL, Watts NB, Miller PD . Chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBDs): what the endocrinologist needs to know. Endocr Pract 2014; 20: 500\u2013516.","journal-title":"Endocr Pract"},{"key":"BFboneres201444_CR57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/ki.2013.271","volume":"85","author":"Y Fang","year":"2014","unstructured":"Fang Y, Ginsburg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA . Early chronic kidney disease\u2013mineral bone disorder stimulates vascular calcification. Kidney Int 2014; 85: 142\u2013150.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR58","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1053\/j.ajkd.2007.02.264","volume":"49","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Hayden JA, Beyene J . Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49: 674\u2013681.","journal-title":"Am J Kidney Dis"},{"key":"BFboneres201444_CR59","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00198-012-1908-y","volume":"23","author":"S Jamal","year":"2012","unstructured":"Jamal S, Cheung AM, West S, Lok C . Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 2012; 23: 2805\u20132813.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR60","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/sdi.12267","volume":"27","author":"SL West","year":"2014","unstructured":"West SL, Jamal SA . The interpretation and utility of bone mineral by dual energy X-ray absorptiometry in chronic kidney disease. Semin Dial 2014; 27: 569\u2013571.","journal-title":"Semin Dial"},{"key":"BFboneres201444_CR61","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jbmr.1885","volume":"28","author":"BF Boyce","year":"2013","unstructured":"Boyce BF . Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res 2013; 28: 711\u2013722.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR62","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/jbmr.1820","volume":"28","author":"FM Takyar","year":"2013","unstructured":"Takyar FM, Tonna S, Ho PW et al. Ephrin B2\/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res. 2013; 28: 912\u2013925.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR63","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrendo.2013.154","volume":"9","author":"E Canalis","year":"2013","unstructured":"Canalis E . Wnt signaling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 2013; 9: 575\u2013583.","journal-title":"Nat Rev Endocrinol"},{"key":"BFboneres201444_CR64","doi-asserted-by":"publisher","first-page":"29809","DOI":"10.1074\/jbc.M113.485938","volume":"288","author":"Y Rhee","year":"2013","unstructured":"Rhee Y, Lee EY, Lezcano V et al. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem 2013; 288: 29809\u201329820.","journal-title":"J Biol Chem"},{"key":"BFboneres201444_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/0022034513500306","volume":"92","author":"BF Boyce","year":"2013","unstructured":"Boyce BF . Advances in the regulation of osteoblasts and osteoclasts functions. J Dent Res 2013; 92: 860\u2013867.","journal-title":"J Dent Res"},{"key":"BFboneres201444_CR66","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF . The amazing osteocyte. J Bone Miner Res 2011; 26: 229\u2013238.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR67","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.bone.2009.03.671","volume":"44","author":"K Hernrisksen","year":"2009","unstructured":"Hernrisksen K, Neutzsky-Wulff AV, Bonewald LF, Kardsal MA . Local communication on and within the bone controls bone remodeling. Bone 2009; 44: 1026\u20131033.","journal-title":"Bone"},{"key":"BFboneres201444_CR68","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bone.2007.12.224","volume":"42","author":"LF Bonewald","year":"2008","unstructured":"Bonewald LF, Johnson ML . Osteocytes, mechanosensing and Wnt signaling. Bone 2008; 42: 606\u2013615.","journal-title":"Bone"},{"key":"BFboneres201444_CR69","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/bonekey.2013.183","volume":"2","author":"A Teti","year":"2013","unstructured":"Teti A . Mechanisms of osteoclast-dependent bone formation. Bonekey Rep 2013; 2: 449.","journal-title":"Bonekey Rep"},{"key":"BFboneres201444_CR70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1017\/S002966510800699X","volume":"67","author":"R Eastell","year":"2008","unstructured":"Eastell R, Hannon RA . Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 2008; 67: 157\u2013162.","journal-title":"Proc Nutr Soc"},{"key":"BFboneres201444_CR71","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00198-009-0838-9","volume":"20","author":"R Civitelli","year":"2009","unstructured":"Civitelli R, Armamento-Villareal R, Napoli N . Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009; 20: 843\u2013851.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jocd.2011.05.008","volume":"14","author":"EV McCloskey","year":"2011","unstructured":"McCloskey EV, Vasikaran S, Cooper C ; FRAX\u00ae Position Development Conference Members. Official positions for FRAX\u00ae clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX\u00ae. J Clin Densitom 2011; 14: 220\u2013222.","journal-title":"J Clin Densitom"},{"key":"BFboneres201444_CR73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1359\/JBMR.051011","volume":"21","author":"PM Chavassieux","year":"2006","unstructured":"Chavassieux PM, Delmas PD . Bone remodeling: biochemical markers or bone biopsy? J Bone Miner Res 2006; 21: 178\u2013179.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR74","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00198-009-0974-2","volume":"21","author":"AL Schafer","year":"2010","unstructured":"Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC . Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 2010; 21: 439\u2013445.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR75","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22: 391\u2013420.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR76","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","volume":"23","author":"D Bauer","year":"2012","unstructured":"Bauer D, Leary E, Silverman S et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012; 23: 2425\u20132433.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR77","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00228-006-0174-3","volume":"62","author":"DJ Lemming","year":"2006","unstructured":"Lemming DJ, Alexandersen P, Kardsal MA, Qvist P, Schaller S, Tank\u00f3 LB . An update of biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006; 62: 781\u2013792.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFboneres201444_CR78","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000057611","volume":"91","author":"G Coen","year":"2002","unstructured":"Coen G, Ballanti P, Bonnucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictively of intact PTH. Nephron 2002; 91: 103\u2013111.","journal-title":"Nephron"},{"key":"BFboneres201444_CR79","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0272-6386(03)00296-8","volume":"41","author":"HH Malluche","year":"2003","unstructured":"Malluche HH, Manier-Faugere MC . Pth 1\u201384, Pth fragmants and bone turnover. Am J Kidney Dis 2003; 41: 1127.","journal-title":"Am J Kidney Dis"},{"key":"BFboneres201444_CR80","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/ndt\/13.9.2294","volume":"13","author":"G Coen","year":"1998","unstructured":"Coen G, Ballanti P, Bonnucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294\u20132302.","journal-title":"Nephrol Dial Transplant"},{"key":"BFboneres201444_CR81","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/oxfordjournals.ndt.a027457","volume":"11","author":"MM Couttenye","year":"1996","unstructured":"Couttenye MM, D\u2019Haese PC, van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065\u20131072.","journal-title":"Nephrol Dial Transplant"},{"key":"BFboneres201444_CR82","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","volume":"25","author":"JH Krege","year":"2014","unstructured":"Krege JH, Lane NE, Harris JM, Miller PD . PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 2014; 25: 2159\u20132171.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR83","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1359\/jbmr.070510","volume":"22","author":"LC Hofbauer","year":"2007","unstructured":"Hofbauer LC, Brueck CC, Singh SK et al. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007; 22: 1317\u20131328.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR84","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/B:REMD.0000032415.83124.20","volume":"5","author":"AM Inzerillo","year":"2004","unstructured":"Inzerillo AM, Epstein S . Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 2004; 5: 261\u2013268.","journal-title":"Rev Endocr Metab Disord"},{"key":"BFboneres201444_CR85","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cell.2010.07.001","volume":"142","author":"CJ Rosen","year":"2010","unstructured":"Rosen CJ, Motyl KJ . No bones about it: insulin modulates skeletal remodeling. Cell 2010; 142: 198\u2013200.","journal-title":"Cell"},{"key":"BFboneres201444_CR86","first-page":"117","volume":"18","author":"G Coen","year":"2005","unstructured":"Coen G . Adynamic bone disease: an update and overview. J Nephrol 2005; 18: 117\u2013122.","journal-title":"J Nephrol"},{"key":"BFboneres201444_CR87","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jbmr.2106","volume":"29","author":"JN Farr","year":"2014","unstructured":"Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S . In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014; 29: 787\u2013795.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR88","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/bonekey.2014.37","volume":"3","author":"PD Miller","year":"2014","unstructured":"Miller PD . Osteoporosis in patients with chronic kidney disease: diagnosis, evaluation and management. BoneKEy Rep 2014; 3: 542.","journal-title":"BoneKEy Rep"},{"key":"BFboneres201444_CR89","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3949\/ccjm.76a.08108","volume":"76","author":"PD Miller","year":"2009","unstructured":"Miller PD . Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med 2009; 76: 715\u2013723.","journal-title":"Cleve Clin J Med"},{"key":"BFboneres201444_CR90","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.beem.2008.07.004","volume":"22","author":"PD Miller","year":"2008","unstructured":"Miller PD . Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008; 22: 849\u2013868.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"BFboneres201444_CR91","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733\u2013759.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR92","first-page":"1859","volume-title":"Osteoporosis 2013","author":"DL Diab","year":"2013","unstructured":"Diab DL, Watts NB, Miller PD . Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Dempster D, Lucket M, Cauley J, (ed.) Osteoporosis 2013. 4th ed. Waltham, MA: Academic Press, 2013: 1859\u20131872."},{"key":"BFboneres201444_CR93","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","volume":"22","author":"A L\u00fche","year":"2008","unstructured":"L\u00fche A, K\u00fcnkele KP, Haiker M et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008; 22: 899\u2013909.","journal-title":"Toxicol In Vitro"},{"key":"BFboneres201444_CR94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","volume":"49","author":"PD Miller","year":"2011","unstructured":"Miller PD . The kidney and bisphosphonates. Bone 2011; 49: 77\u201381.","journal-title":"Bone"},{"key":"BFboneres201444_CR95","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281\u2013289.","journal-title":"Kidney Int"},{"key":"BFboneres201444_CR96","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.bone.2011.09.035","volume":"49","author":"PD Miller","year":"2011","unstructured":"Miller PD, Ragi-Eis S, Mautalan C, Ramimeriz F, Jonkamski I . Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease\u2014the DIVINE study. Bone 2011; 49: 1317\u20131322.","journal-title":"Bone"},{"key":"BFboneres201444_CR97","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735\u20131744.","journal-title":"Cancer"},{"key":"BFboneres201444_CR98","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458\u20131468.","journal-title":"J Natl Cancer Inst"},{"key":"BFboneres201444_CR99","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22: 503\u2013508.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR100","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE . Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105\u20132115.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR101","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G . Bisphosphonates for osteoporosis\u2014where do we go from here? N Engl J Med 2012; 366: 2048\u20132051.","journal-title":"N Engl J Med"},{"key":"BFboneres201444_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1\u201323.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR103","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927\u20132938.","journal-title":"JAMA"},{"key":"BFboneres201444_CR104","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012; 97: 2272\u20132282.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres201444_CR105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126: 13\u201320.","journal-title":"Am J Med"},{"key":"BFboneres201444_CR106","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00198-010-1444-6","volume":"22","author":"PN Sambrook","year":"2011","unstructured":"Sambrook PN, Cameron ID, Chen JS et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011; 22: 2551\u20132556.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR107","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrendo.2012.36","volume":"8","author":"B Thompson","year":"2012","unstructured":"Thompson B, Towler DA . Arterial calcification and bone physiology: role of the bone\u2013vascular axis. Nat Rev Endocrinol 2012; 8: 529\u2013543.","journal-title":"Nat Rev Endocrinol"},{"key":"BFboneres201444_CR108","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mayocp.2012.08.019","volume":"88","author":"P Peris","year":"2013","unstructured":"Peris P, Atkinson EJ, G\u00f6ssl M et al. Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. Mayo Clin Proc 2013; 88: 46\u201355.","journal-title":"Mayo Clin Proc"},{"key":"BFboneres201444_CR109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4137\/CMED.S10007","volume":"5","author":"LL Santos","year":"2012","unstructured":"Santos LL, Cavalcanti TB, Bandeira FA . Vascular effects of bisphosphonates\u2014a systematic review. Clin Med Insights Endocrinol Diabetes 2012; 5: 47\u201354.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"BFboneres201444_CR110","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1525-139X.2007.00300.x","volume":"20","author":"KA Hruska","year":"2007","unstructured":"Hruska KA, Saab G, Mattew S, Lund R . Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20: 309\u2013315.","journal-title":"Semin Dial"},{"key":"BFboneres201444_CR111","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","volume":"7","author":"PD Miller","year":"2009","unstructured":"Miller PD . Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009; 7: 18\u201322.","journal-title":"Curr Osteoporos Rep"},{"key":"BFboneres201444_CR112","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1759720X11424220","volume":"3","author":"PD Miller","year":"2011","unstructured":"Miller PD . A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2011; 3: 271\u2013282.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"BFboneres201444_CR113","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP et al. on behalf of the Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010; 25: 2256\u20132265.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR114","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al. for the AMG 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43: 222\u2013229.","journal-title":"Bone"},{"key":"BFboneres201444_CR115","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al. For the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756\u2013765.","journal-title":"N Engl J Med"},{"key":"BFboneres201444_CR116","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Lewiecki EM, Geller ML et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013; 24: 227\u2013235.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR117","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72\u201381.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR118","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D . A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471\u20131479.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR119","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011; 26: 1829\u20131835.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR120","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00774-013-0506-1","volume":"32","author":"SL West","year":"2014","unstructured":"West SL, Lokb CE, Jamal SA . Osteoprotegerin and fractures in men and women with chronic kidney disease. J Bone Miner Metab 2014; 32: 428\u2013433.","journal-title":"J Bone Miner Metab"},{"key":"BFboneres201444_CR121","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","volume":"16","author":"PJ Bekker","year":"2001","unstructured":"Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR . The effect of a single dose of osteoprotogerin in postmenopausal women. J Bone Miner Res 2001; 16: 348\u2013360.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR122","unstructured":"Egbuna OI, Cheung AM, Siddhanti S, Wang A, Daizadeh N, Anthony M . Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification. J Bone Miner Res 2013; in press."},{"key":"BFboneres201444_CR123","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4158\/EP.10.2.139","volume":"10","author":"PD Miller","year":"2004","unstructured":"Miller PD, Bilezikian JP, Deal C, Harris ST, Ci RP . Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004; 10: 139\u2013148.","journal-title":"Endocr Pract"},{"key":"BFboneres201444_CR124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9\u201317.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR125","first-page":"3069","volume":"85","author":"ES Kurland","year":"2000","unstructured":"Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP . Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069\u20133076.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres201444_CR126","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028\u20132039.","journal-title":"N Engl J Med"},{"key":"BFboneres201444_CR127","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1359\/jbmr.090105","volume":"24","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian JP, Matsumoto T, Bellido T et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2009; 24: 373\u2013385.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR128","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434\u20131441.","journal-title":"N Engl J Med"},{"key":"BFboneres201444_CR129","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007; 18: 59\u201368.","journal-title":"Osteoporos Int"},{"key":"BFboneres201444_CR130","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846\u20131853.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR131","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1359\/JBMR.041016","volume":"20","author":"P Chen","year":"2005","unstructured":"Chen P, Miller PD, Delmas PD, Misurski DA, Krege JK . Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res 2005; 20(Suppl 1): S5.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR132","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5301\/jn.5000212","volume":"26","author":"JB Cannata-And\u00eda","year":"2013","unstructured":"Cannata-And\u00eda JB, Rodriguez Garc\u00eda M, G\u00f3mez Alonso C . Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol 2013; 26: 73\u201380.","journal-title":"J Nephrol"},{"key":"BFboneres201444_CR133","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MNH.0b013e32832c4df0","volume":"18","author":"JM Fraz\u00e3o","year":"2009","unstructured":"Fraz\u00e3o JM, Martins P . Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 2009; 18: 303\u2013307.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFboneres201444_CR134","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024\u20132030.","journal-title":"Arch Intern Med"},{"issue":"5","key":"BFboneres201444_CR135","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.semarthrit.2014.09.005","volume":"44","author":"Paul D. Miller","year":"2015","unstructured":"Miller PD, McCarthy EF . Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 2014; doi: 10.1016\/j.semarthrit.2014.09.005. [Epub ahead of print]","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"BFboneres201444_CR136","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coph.2014.03.004","volume":"16","author":"KW Ng","year":"2014","unstructured":"Ng KW, Martin TJ . New therapeutics for osteoporosis. Curr Opin Pharmacol 2014; 16: 58\u201363.","journal-title":"Curr Opin Pharmacol"},{"key":"BFboneres201444_CR137","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/jbmr.2211","volume":"29","author":"BL Pennypacker","year":"2014","unstructured":"Pennypacker BL, Chen CM, Zheng H et al. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J Bone Miner Res 2014; 29: 1847\u20131858.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR138","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/CJN.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D . The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819\u2013823.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFboneres201444_CR139","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF . The amazing osteocyte. J Bone Miner Res 2011; 26: 229\u2013238.","journal-title":"J Bone Miner Res"},{"key":"BFboneres201444_CR140","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A . Romosozumab in postmenopausal women with osteopenia. N Engl J Med 2014; 370: 1664\u20131665.","journal-title":"N Engl J Med"},{"issue":"2","key":"BFboneres201444_CR141","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"Robert R. Recker","year":"2015","unstructured":"Recker R, Benson C, Matsumoto T et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2014; doi: 10.1002\/jbmr.2351. [Epub ahead of print]","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"BFboneres201444_CR142","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1517\/13543784.2015.973021","volume":"24","author":"Stergios A Polyzos","year":"2014","unstructured":"Polyzos SA, Makras P, Efstathiadou Z, Anastasilakis AD . Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opin Investig Drugs 2014; doi: 10.1517\/13543784.2015.973021. [Epub ahead of print]","journal-title":"Expert Opinion on Investigational Drugs"}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/boneres201444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/boneres201444","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/boneres201444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:00:40Z","timestamp":1672959640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/boneres201444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,23]]}},"alternative-id":["BFboneres201444"],"URL":"https:\/\/doi.org\/10.1038\/boneres.2014.44","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]},"assertion":[{"value":"24 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14044"}}